In order to address the possibility whether or not the p90/CIP2A might be a tumor-associated antigen (TAA) and a useful biomarker in lung cancer, they used the full-length recombinant p90/CIP2A protein as the antigen in an enzyme-linked immunoassay (ELISA) and Western blotting was performed for the detection of auto-antibodies in 105 sera from patients. This evidence concerns the gene CIP2A and lung cancer.